These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 12479396)

  • 1. Ultraviolet-irradiated vaccinia virus recombinants, exposing HIV-envelope on their outer membrane, induce antibodies against this antigen in rabbits.
    Loewinger M; Katz E
    Viral Immunol; 2002; 15(3):473-9. PubMed ID: 12479396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of recombinant vaccinia viruses that display the HIV type 1 envelope glycoprotein on the surface of infectious virions.
    Katz E; Moss B
    AIDS Res Hum Retroviruses; 1997 Nov; 13(17):1497-500. PubMed ID: 9390748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cytoplasmic and transmembrane domains of the vaccinia virus B5R protein target a chimeric human immunodeficiency virus type 1 glycoprotein to the outer envelope of nascent vaccinia virions.
    Katz E; Wolffe EJ; Moss B
    J Virol; 1997 Apr; 71(4):3178-87. PubMed ID: 9060681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner.
    Gherardi MM; Ramirez JC; Rodríguez D; Rodríguez JR; Sano G; Zavala F; Esteban M
    J Immunol; 1999 Jun; 162(11):6724-33. PubMed ID: 10352291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral immune response elicited by highly attenuated variants of vaccinia virus and by an attenuated recombinant expressing HIV-1 envelope protein.
    Dallo S; Maa JS; Rodriguez JR; Rodriguez D; Esteban M
    Virology; 1989 Nov; 173(1):323-9. PubMed ID: 2510402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.
    Richmond JF; Mustafa F; Lu S; Santoro JC; Weng J; O'Connell M; Fenyö EM; Hurwitz JL; Montefiori DC; Robinson HL
    Virology; 1997 Apr; 230(2):265-74. PubMed ID: 9143282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization of rabbits with a modified vaccinia Ankara recombinant virus bearing the HIV envelope antigen on its outer membrane.
    Barchichat S; Katz E
    Virus Res; 2002 Dec; 90(1-2):243-51. PubMed ID: 12457978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenovirus vectored vaccines.
    Natuk RJ; Davis AR; Chanda PK; Lubeck MD; Chengalvala M; Murthy SC; Wade MS; Dheer SK; Bhat BM; Murthy KK
    Dev Biol Stand; 1994; 82():71-7. PubMed ID: 7958485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach.
    Tan GS; McKenna PM; Koser ML; McLinden R; Kim JH; McGettigan JP; Schnell MJ
    Virology; 2005 Jan; 331(1):82-93. PubMed ID: 15582655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 vaccines based on replication-competent Tiantan vaccinia protected Chinese rhesus macaques from simian HIV infection.
    Liu Q; Li Y; Luo Z; Yang G; Liu Y; Liu Y; Sun M; Dai J; Li Q; Qin C; Shao Y
    AIDS; 2015 Mar; 29(6):649-58. PubMed ID: 25849828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of recombinants based on the genetically-engineered vaccinia strain, NYVAC.
    Tartaglia J; Cox WI; Pincus S; Paoletti E
    Dev Biol Stand; 1994; 82():125-9. PubMed ID: 7958466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.
    Shinoda K; Xin KQ; Kojima Y; Saha S; Okuda K; Okuda K
    Clin Immunol; 2006 Apr; 119(1):32-7. PubMed ID: 16458074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens.
    Galmiche MC; Goenaga J; Wittek R; Rindisbacher L
    Virology; 1999 Feb; 254(1):71-80. PubMed ID: 9927575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of persistent infections with vaccinia virus recombinants to introduce alterations in foreign proteins: an application to HIV-1 env protein.
    Esteban M; Ramón Rodríguez J; Jimenez V; Rodríguez D
    Virus Res; 1996 Dec; 46(1-2):45-56. PubMed ID: 9029776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
    Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
    Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees.
    Perales MA; Schwartz DH; Fabry JA; Lieberman J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):27-35. PubMed ID: 7648281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of different promoters on the virulence and immunogenicity of a HIV-1 Env-expressing recombinant vaccinia vaccine.
    Isshiki M; Zhang X; Sato H; Ohashi T; Inoue M; Shida H
    Vaccine; 2014 Feb; 32(7):839-45. PubMed ID: 24370703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction of vaccinia virus recombinants expressing several measles virus proteins and analysis of their efficacy in vaccination of mice.
    Wild TF; Bernard A; Spehner D; Drillien R
    J Gen Virol; 1992 Feb; 73 ( Pt 2)():359-67. PubMed ID: 1538193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein.
    Cox WI; Tartaglia J; Paoletti E
    Virology; 1993 Aug; 195(2):845-50. PubMed ID: 8337851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.